Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ACIU

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

AC Immune Ltd

ACIU
Current price
1.99 USD -0.09 USD (-4.33%)
Last closed 2.07 USD
ISIN CH0329023102
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 208 242 000 USD
Yield for 12 month -42.98 %
1Y
3Y
5Y
10Y
15Y
ACIU
21.11.2021 - 28.11.2021

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

9.58 USD

P/E Ratio

Dividend Yield

Financials ACIU

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+34 381 043 USD

Last Year

+18 633 924 USD

Current Quarter

+1 246 374 USD

Last Quarter

+1 431 442 USD

Current Year

+34 381 043 USD

Last Year

-50 113 055 USD

Current Quarter

+1 246 374 USD

Last Quarter

+1 431 442 USD
EBITDA -50 223 000 USD
Operating Margin TTM -1 956.57 %
Price to Earnings
Return On Assets TTM -17.07 %
PEG Ratio
Return On Equity TTM -43.50 %
Wall Street Target Price 9.58 USD
Revenue TTM 28 299 000 USD
Book Value 0.94 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -92.30 %
Dividend Yield
Gross Profit TTM -35 022 000 USD
Earnings per share -0.66 USD
Diluted Eps TTM -0.66 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -184.04 %

Stock Valuation ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 11.24
Enterprise Value Revenue 0.86
Price Sales TTM 7.36
Enterprise Value EBITDA -0.76
Price Book MRQ 1.74

Technical Indicators ACIU

For 52 Weeks

1.43 USD 4.26 USD
50 Day MA 1.80 USD
Shares Short Prior Month 1 386 325
200 Day MA 2.53 USD
Short Ratio 11.55
Shares Short 1 363 283
Short Percent 2.86 %